Our Pipeline

High-value asset development focused on oncology

We are building a pipeline of uniquely matched ADCs. Currently we are advancing four proprietary therapeutic programs for the treatment of blood cancers as well as solid tumors. Our lead candidate, Tub-010 targets CD30 and is designed to treat lymphoma patients.

Tubulis Pipeline